CYTOKINETICS INCORPORATED - COMMON STOCK
41.96
14-February-25 11:05:25
15 minutes delayed
Stocks
+0.34
+0.80%
Today's range
41.10 - 42.62
ISIN
N/A
Source
NASDAQ
-
02 Dec 2024 07:30:00 By Nasdaq GlobeNewswire
-
Cytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in Japan
19 Nov 2024 02:30:00 By Nasdaq GlobeNewswire
-
16 Nov 2024 09:00:00 By Nasdaq GlobeNewswire
-
16 Nov 2024 09:00:00 By Nasdaq GlobeNewswire
-
Cytokinetics to Participate in the 2024 Jefferies London Healthcare Conference
12 Nov 2024 16:00:00 By Nasdaq GlobeNewswire
-
Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4015089
11 Nov 2024 07:30:00 By Nasdaq GlobeNewswire
-
Cytokinetics Reports Third Quarter 2024 Financial Results
06 Nov 2024 16:00:00 By Nasdaq GlobeNewswire
-
05 Nov 2024 16:00:00 By Nasdaq GlobeNewswire
-
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Nov 2024 16:00:00 By Nasdaq GlobeNewswire
-
Cytokinetics to Announce Third Quarter Results on November 6, 2024
23 Oct 2024 16:00:00 By Nasdaq GlobeNewswire
-
16 Oct 2024 07:30:00 By Nasdaq GlobeNewswire
-
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Oct 2024 16:00:00 By Nasdaq GlobeNewswire
-
Cytokinetics to Host Investor & Analyst Day on October 16, 2024
02 Oct 2024 16:00:00 By Nasdaq GlobeNewswire
-
Cytokinetics Presents Additional Data From SEQUOIA-HCM at the HFSA Annual Scientific Meeting
30 Sep 2024 09:20:00 By Nasdaq GlobeNewswire
-
Cytokinetics Presents Additional Data from SEQUOIA-HCM at the HCMS Scientific Sessions
27 Sep 2024 11:00:00 By Nasdaq GlobeNewswire
-
Cytokinetics Announces Call for Proposals for Its Seventh Annual Communications Grant Program
24 Sep 2024 07:30:00 By Nasdaq GlobeNewswire
-
19 Sep 2024 16:00:00 By Nasdaq GlobeNewswire
-
Cytokinetics Announces Data From Phase 1 Study of CK-4021586
09 Sep 2024 07:30:00 By Nasdaq GlobeNewswire
-
05 Sep 2024 16:00:00 By Nasdaq GlobeNewswire
-
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Sep 2024 16:00:00 By Nasdaq GlobeNewswire